Navigation Links
Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Date:4/1/2011

ication (MAA) with the European Medicines Agency (EMA) for fidaxomicin. Pruvel™ is a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea.  Additional information can be found at http://www.optimerpharma.com.

Contacts

Optimer Pharmaceuticals, Inc.
Christina Donaghy, Corporate Communications Manager
John D. Prunty, Chief Financial Officer & VP Finance
858-909-0736

Canale Communications, Inc.
Jason I. Spark, Senior Vice President
619-849-6005


'/>"/>
SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Optimer Pharmaceuticals, Inc. Announces Exercise in Full of Underwriters Option to Purchase Additional Shares and Closing of Public Offering of Common Stock
2. Optimer Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
3. Optimer Pharmaceuticals to Present at Oppenheimer Healthcare Conference
4. Optimer Pharmaceuticals Announces Presentations at Upcoming IDSA Annual Meeting
5. Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC
6. Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
7. Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
8. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
9. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
10. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
11. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... TN (PRWEB) , ... July 02, 2015 , ... ... the development and manufacturing of surgical instruments in Orthopedics, announced today the acquisition ... contract-manufacturing and the world's largest provider of surgical instruments to the Spine Industry. ...
(Date:7/1/2015)... 1, 2015   Decision Resources Group ... of Otezla are its oral administration, alternative mechanism ... by surveyed rheumatologists. Otezla was the first oral ... of active psoriatic arthritis in the ... care includes conventional oral treatments including disease-modifying antirheumatic ...
(Date:7/1/2015)... , July 1, 2015   Neuraltus ... the development of groundbreaking drugs to treat neurodegenerative ... today that Robert G. Miller , M.D., Director ... Sutter Health,s California Pacific Medical Center in San Francisco, ... Association for $1.5 million to help fund a ...
(Date:7/1/2015)... ... 2015 , ... A newly launched business plan contest will ask startup companies ... in life sciences R&D. The Pistoia Alliance President’s Startup Challenge 2015 will see small ... period of expert mentorship from a senior industry figure drawn from the Pistoia Alliance ...
Breaking Biology Technology:In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3
... the Gladstone Institute of Neurological Disease (GIND) have uncovered ... (AD) and other neurodegenerative diseases. The results might lead ... examined a protein called tau that has been strongly ... author on the study. "Tau forms toxic protein aggregations ...
... Maui County officials at that time agreed with ... that someone with their experience in scrap metal ... In March of 2005, the headline of the Maui ... Stepping into this island-wide disaster was SOS Metals ...
... Sept. 22 Signal Genetics, a privately held predictive ... company will work with Array BioPharma to help push ... helping bring personalized medicine and companion diagnostics to patients ... and antibody producing cells. Signal Genetics, groundbreaking ...
Cached Biology Technology:Gladstone scientists identify strategy to reduce toxic proteins associated with Alzheimer's disease 2SOS Metals Island Recycling Sold to Schnitzer Steel Industries 2
(Date:6/24/2015)... 24, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced that Sharp has selected its industry-leading ... for its latest flagship smartphone device, the AQUOS ... million shipments of its fingerprint ID sensor technology, ... scalability and leadership in the biometrics market through ...
(Date:6/24/2015)... MARTIGNY, Switzerland , June 24, 2015 /PRNewswire/ ... strategic partnership with emerging biometric password solution one ... http://photos.prnewswire.com/prnh/20150623/225014LOGO one face in, ... offers a ground-breaking and affordable multifactor-authentication biometric answer ... speaker recognition technology, provided in partnership with KeyLemon, ...
(Date:6/23/2015)... Research and Markets( ... "Body-Worn Temperature Sensors Market - Global Industry ... - 2020" report to their offering. ... global body-worn temperature sensors market. The global body-worn ... basis of types, care setting, patient demographic, applications ...
Breaking Biology News(10 mins):Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2Body-Worn Temperature Sensors Market - Global Industry Analysis 2
... is available in German . , ... has developed a model, which identifies potential habitats and corridors ... Rheinland-Pfalz as an example, it was demonstrated that almost half ... enabling a maximum population of 1600 females. The model can ...
... is a link between alcohol consumption and increased risk of ... 5,870 young adult women. The study, published in ... found that the risk increased 3% for every additional alcoholic ... observe any increase in risk of seasonal allergic rhinitis according ...
... Achieves record biometric revenues and profitability, WALL, ... Board: BKYI), a leader in wireless public safety ... profitability and strong revenue growth for its second ... continuing operations for the quarter ended June 30,2008 ...
Cached Biology News:Let the cat keep chasing the mouse 2Let the cat keep chasing the mouse 3Let the cat keep chasing the mouse 4Alcohol is associated with risk of perennial allergic rhinitis 2BIO-key(R) Reports Profitability on Strong Revenue Growth for Second Quarter 2008 2BIO-key(R) Reports Profitability on Strong Revenue Growth for Second Quarter 2008 3BIO-key(R) Reports Profitability on Strong Revenue Growth for Second Quarter 2008 4BIO-key(R) Reports Profitability on Strong Revenue Growth for Second Quarter 2008 5
... Morris Water MazeRecords animal movements in a ... subjects at once in a predefined sequence of ... instruments all built around a video camera, frame ... track two fields at once and up to ...
... Place AvoidanceIncludes all features of Tracker, plus ... a user defined subsection of the arena, and ... family of instruments all built around a video ... that can track two fields at once and ...
... Last innovation from Magnetofection technology, ... delivery system available. Simple, rapid and ... compatible and non toxic. Specifically designed ... gene silencing at very low doses ...
Denhardt's Solution is a mixture of blocking agents used in membrane-based hybridization protocols. The solution contains 1% Ficoll (type 400) 1% polyvinylpyrrolidone and 1% bovine serum albumin. Ste...
Biology Products: